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» INTRODUCTION
Double-blind, Randomised, Placebo Controlled, Parallel 
Group Study of Sativex® in the Treatment of Patients With 
Peripheral Neuropathic Pain, Associated With Allodynia
Serpell MG1, Ratcliffe SHR2, Hovorka J3 & Schofield M4.
1Gartnavel General, Univ. of Glasgow, UK; 2MAC UK Neuroscience Ltd., Manchester, UK; 3Neurologicke oddeleni, Prague, CZ; 4West 
Suffolk Hospital, Bury St Edmunds, UK.
» METHODS
» RESULTS
Study drug:  Sativex®
 
(THC:CBD) endocannabinoid system modulator
• Derived from highly standardised botanical extract;
• Formulated into a spray for sublingual/oromucosal administration;
•
 
Highly standardised formulation, each 100µl spray of Sativex®
 
contains 2.7 mg Δ9-
 
tetrahydrocannabinol (THC), 2.5mg cannabidiol (CBD), and small amounts of other 
cannabinoids;
• Approved in Canada for relief of central neuropathic pain in MS and cancer pain.
PRIMARY ENDPOINTS
» DISCUSSION
• These data support the efficacy of Sativex in relieving PNP and substantiate its safety profile in patients
• Sativex improved both the pain and sleep parameters measured
• There were no signs of tolerance; pain relief was maintained without an increase in dose
REFERENCES: 1Rog D, Nurmikko
 
T, Friede
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» CONCLUSION
•
 
Patients taking Sativex obtained clinically important improvements in their pain and 
quality of sleep over and above currently available treatments
•
 
This was achieved in a meaningful proportion of otherwise treatment-resistant patients
•
 
The difference in analgesic effect between Sativex and placebo was smaller than 
previously observed, possibly due to
1.
 
A higher use of rescue analgesic use in the placebo group compared with 
the Sativex group;
2.
 
The very high placebo response seen, which increased maximally as the 
number of sprays increased
Peripheral Neuropathic Pain (PNP): 
• Management of PNP is a significant challenge;
• Currently the most difficult pain to treat;
• Current therapies have a limited effect on PNP and can cause side effects;
• Recent research indicates that cannabinoids have therapeutic potential1,2;
•
 
This study aimed to evaluate the long term efficacy of Sativex
 
in relieving chronic PNP 
and to assess the safety of Sativex in study patients with PNP associated with allodynia.
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Study Schema
•
 
A 15-week (one-week baseline and 14-week treatment period), multicentre,  double blind, 
randomised, placebo controlled parallel group study;
•
 
Patients randomised to either Sativex or placebo and self-titrated study medication based on 
efficacy and tolerability, up to a maximum of 24 sprays/day;
•
 
Patients had chronic (≥six months) PNP associated with allodynia, and secondary to post-herpetic 
neuralgia, peripheral neuropathy or focal nerve lesion or Complex Regional Pain Syndrome type 2.
Primary Endpoints:
-
 
Change from baseline in 0-10 numerical rating scale (0-10 NRS) pain severity scores
-
 
Responder analysis (≥30% decrease in 0-10 NRS pain severity score from baseline)
Secondary Endpoints:
-
 
Neuropathic pain scale (NPS)
 
-
 
Brief pain inventory (BPI)
-
 
Sleep quality 0-10 NRS
 
-
 
Rescue analgesic use
-
 
Subject global impression of change (SGIC)
 
-
 
Quality of life questionnaire (EQ-5D)
Safety Endpoints:
-
 
Adverse Event (AE) monitoring 
PATIENT DISPOSITION
7-day baseline period
The two treatment groups were closely matched for all demographic and baseline characteristics.
Screened (n=303)
Sativex (n=128)
Withdrawn (n=24):
AE (7), withdrew 
consent (3), lost to 
follow up (1), lack 
of efficacy (12), 
other (1)
Withdrawn (n=49):
AE (24), withdrew 
consent (7), lost to 
follow up (7), lack 
of efficacy (11), 
other (0)
Completed (n=94)Completed (n=79)
Full analysis set (n=240) 
Per protocol set (n=163) 
Safety set (n=246)
Randomised (n=246)
Placebo (n=118)
7-day baseline period
0-10 NRS Pain Scores: Responder 
Analysis – Proportion of patients with at 
least a 30% improvement from baseline 
in the primary evaluable period
•
 
The pain responder analysis was 
statistically significant in favour of Sativex 
with an odds ratio of 1.97.
•
 
The change in pain 0-10 NRS from 
baseline was -1.05 for Sativex and -0.71 
for placebo (-0.34 treatment difference in 
favour of Sativex), but this was not 
statistically significant.
•
 
For 30% responders, the proportion of 
responders was observed to increase 
much more quickly in relation to the dose 
of Sativex compared with placebo 
(illustrated below). Explain better??
•
 
At around 14-15 sprays per day, the 
response rate in patients receiving Sativex 
began to slow down whilst for those taking 
placebo, the proportion of responders was 
still increasing maximally. 
SECONDARY ENDPOINTS
98 days 
treatment 
Cumulative Percent at the 30% Response by Mean Sprays
Adverse Events
• Study medication was well tolerated
• Most AEs were mild or moderate in severity and resolved
• The most commonly reported treatment related AEs were dizziness, nausea and fatigue
•
 
AEs were the commonest reason for study withdrawal (24 [33%] Sativex patients vs 7 
[10%] placebo patients)
• There were no treatment-related serious AEs
SGIC
•
 
There was a statistically significant treatment difference for a positive response in favour of 
Sativex.
Rescue Analgesic Use
• On average, the Sativex group used fewer doses of rescue analgesic than the placebo group.
•X (SD) vs. Y (SD)
• On average , the Sativex group used fewer spray of study medication than the placebo group.
•X (SD) vs. Y (SD)
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Sleep Quality Assessment
•
 
The adjusted mean sleep quality rating score for the Sativex group showed an 
improvement of 1.57 points from a mean baseline score off 5.4 points, compared with an 
adjusted decrease of 0.74 points from a baseline of 5.8 points for placebo.
•
 
The estimated treatment difference of -0.83 points in favour of Sativex was highly 
statistically significant (p=0.01).
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